Antigen Potency and Maximal Efficacy Reveal a Mechanism of Efficient T Cell Activation

被引:58
作者
Dushek, Omer [1 ,2 ]
Aleksic, Milos [1 ]
Wheeler, Richard J. [1 ]
Zhang, Hao [1 ]
Cordoba, Shaun-Paul [1 ]
Peng, Yan-Chun [3 ]
Chen, Ji-Li [3 ]
Cerundolo, Vincenzo [3 ]
Dong, Tao [3 ]
Coombs, Daniel [4 ,5 ]
van der Merwe, Philip Anton [1 ]
机构
[1] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England
[2] Univ Oxford, Ctr Math Biol, Oxford OX1 3LB, England
[3] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England
[4] Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z2, Canada
[5] Univ British Columbia, Inst Appl Math, Vancouver, BC V6T 1Z2, Canada
基金
英国生物技术与生命科学研究理事会; 英国医学研究理事会; 英国惠康基金;
关键词
RECEPTOR LIGANDS; TCR ENGAGEMENT; PHAGE DISPLAY; HIGH-AFFINITY; DWELL-TIME; IN-VIVO; BINDING; RESPONSES; KINETICS; SINGLE;
D O I
10.1126/scisignal.2001430
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
T cell activation, a critical event in adaptive immune responses, depends on productive interactions between T cell receptors (TCRs) and antigens presented as peptide-bound major histocompatibility complexes (pMHCs). Activated T cells lyse infected cells, secrete cytokines, and perform other effector functions with various efficiencies, which depend on the binding parameters of the TCR-pMHC complex. The mechanism through which binding parameters are translated to the efficiency of T cell activation, however, remains controversial. The "affinity model" suggests that the dissociation constant (K-D) of the TCR-pMHC complex determines the response, whereas the "productive hit rate model" suggests that the off-rate (k(off)) is critical. Here, we used mathematical modeling to show that antigen potency, as determined by the EC50 (half-maximal effective concentration), which is used to support K-D-based models, could not discriminate between the affinity and the productive hit rate models. Both models predicted a correlation between EC50 and K-D, but only the productive hit rate model predicted a correlation between maximal efficacy (E-max), the maximal T cell response induced by pMHC, and k(off). We confirmed the predictions made by the productive hit rate model in experiments with cytotoxic T cell clones and a panel of pMHC variants. Thus, we propose that the activity of an antigen is determined by both its potency (EC50) and maximal efficacy (E-max).
引用
收藏
页数:8
相关论文
共 45 条
[1]   Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time [J].
Aleksic, Milos ;
Dushek, Omer ;
Zhang, Hao ;
Shenderov, Eugene ;
Chen, Ji-Li ;
Cerundolo, Vincenzo ;
Coombs, Daniel ;
van der Merwe, P. Anton .
IMMUNITY, 2010, 32 (02) :163-174
[2]   Modeling T cell antigen discrimination based on feedback control of digital ERK responses [J].
Altan-Bonnet, G ;
Germain, RN .
PLOS BIOLOGY, 2005, 3 (11) :1925-1938
[3]   A response calculus for immobilized T cell receptor ligands [J].
Andersen, PS ;
Menné, C ;
Mariuzza, RA ;
Geisler, C ;
Karjalainen, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :49125-49132
[4]   Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens [J].
Andersen, PS ;
Geisler, C ;
Buus, S ;
Mariuzza, RA ;
Karjalainen, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33452-33457
[5]  
BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575
[6]   Serial triggering of T cell receptors results in incremental accumulation of signaling intermediates [J].
Borovsky, Z ;
Mishan-Eisenberg, G ;
Yaniv, E ;
Rachmilewitz, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21529-21536
[7]  
Boulter JM, 2005, CLIN EXP IMMUNOL, V142, P454
[8]   The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness [J].
Chervin, Adam S. ;
Stone, Jennifer D. ;
Holler, Phillip D. ;
Bai, Ailin ;
Chen, Jianzhu ;
Eisen, Herman N. ;
Kranz, David M. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (02) :1166-1178
[9]   The reaction between acetyl choline and muscle cells. [J].
Clark, AJC .
JOURNAL OF PHYSIOLOGY-LONDON, 1926, 61 (04) :530-546
[10]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924